Stockscreener 앱 받기
14.16
2.16%
0.30
시간 외 거래:
14.16
전일 마감가:
$13.86
열려 있는:
$13.69
하루 거래량:
1.03M
Relative Volume:
0.67
시가총액:
$861.38M
수익:
$10.00M
순이익/손실:
$-113.63M
주가수익비율:
-7.7234
EPS:
-1.8334
순현금흐름:
$-83.28M
1주 성능:
+1.54%
1개월 성능:
+5.51%
6개월 성능:
-39.62%
1년 성능:
-54.19%
1일 변동 폭
$13.60
$14.29
1주일 범위
$13.44
$14.42
52주 변동 폭
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
명칭
Janux Therapeutics Inc
전화
(858) 751-4493
주소
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
14.16 | 843.13M | 10.00M | -113.63M | -83.28M | -1.8334 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-10 | 개시 | Stifel | Buy |
| 2025-09-10 | 개시 | Truist | Buy |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-07-11 | 개시 | Raymond James | Outperform |
| 2024-12-03 | 재확인 | BTIG Research | Buy |
| 2024-12-03 | 재확인 | H.C. Wainwright | Buy |
| 2024-11-22 | 개시 | Leerink Partners | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-09-06 | 개시 | Stifel | Buy |
| 2024-05-30 | 개시 | Scotiabank | Sector Perform |
| 2024-03-21 | 개시 | BTIG Research | Buy |
| 2024-03-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-06 | 개시 | Wedbush | Outperform |
| 2022-11-14 | 개시 | William Blair | Outperform |
모두보기
Janux Therapeutics Inc 주식(JANX)의 최신 뉴스
Precision Trading with Janux Therapeutics Inc. (JANX) Risk Zones - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Veeva Systems (VEEV) and Janux Therapeutics Inc (JANX) - The Globe and Mail
HC Wainwright Expects Higher Earnings for Janux Therapeutics - MarketBeat
JANX PE Ratio & Valuation, Is JANX Overvalued - Intellectia AI
Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring The 316.79% Potential Upside - DirectorsTalk Interviews
JANX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Truist cuts Janux Therapeutics stock price target on competition By Investing.com - Investing.com Canada
Truist Securities Adjusts PT on Janux Therapeutics to $80 From $100, Maintains Buy Rating - marketscreener.com
Janux Therapeutics: Strong Cash Runway, Strategic Bristol-Myers Partnership, and 2026 Clinical Catalysts Underpin Buy Rating - TipRanks
Nuvation Bio Inc. (NUVB) Amends Protocol on Safusidenib Trials in Astrocytoma - Bitget
Janux Therapeutics, Inc. (JANX) Commences Patient Dosing of JANX011 in Autoimmune Trial - Finviz
11 Best Cancer Stocks to Invest In Now - Insider Monkey
Janux Therapeutics JANX Net Loss Deepens To US$113.6 Million Challenging Bullish Growth Narratives - simplywall.st
Key facts: Janux Therapeutics Receives Strong Buy Ratings; Partners with BMS - TradingView
Janux: Encouraging Early T Cell Engager Data, Broad Pipeline, and Strong Cash Runway Support Buy Rating - TipRanks
Cantor Fitzgerald Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price - MarketBeat
Guggenheim Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price - MarketBeat
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Syndax Pharmaceuticals (SNDX) - The Globe and Mail
Janux Therapeutics, Inc. Q4 Loss Rises - Nasdaq
Janux Therapeutics (NASDAQ:JANX) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Janux Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Janux Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q4 Revenue $0 - marketscreener.com
Bristol Myers deal and wider 2025 loss at Janux Therapeutics (JANX) - Stock Titan
Janux Therapeutics Q4 net loss widens on higher R&D expenses - TradingView
BRIEF-Janux Therapeutics Q4 Basic EPS USD -0.51 - TradingView
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Business Wire
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Technical Reactions to JANX Trends in Macro Strategies - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Janux Therapeutics Inc (JANX) and CVS Health (CVS) - The Globe and Mail
Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring A 376% Upside In Biotechnology - DirectorsTalk Interviews
Janux Therapeutics, Inc. (JANX) faces platform risk amid lack of durability data on JANX007 - MSN
Analysts Are Bullish on These Healthcare Stocks: CG Oncology, Inc. (CGON), Qiagen (QGEN) - The Globe and Mail
Why analysts remain bullish on Janux Therapeutics Inc. stockQuarterly Trade Report & Real-Time Chart Pattern Alerts - mfd.ru
Where is Janux Therapeutics (JANX) Headed According to Analysts? - Finviz
Janux Therapeutics (JANX) Expected to Announce Earnings on Thursday - MarketBeat
Analysts Offer Insights on Healthcare Companies: NeurAxis, Inc. (NRXS), Janux Therapeutics Inc (JANX) and BioLife Solutions (BLFS) - The Globe and Mail
Janux therapeutics doses first participant in JANX011 phase 1 trial By Investing.com - Investing.com Australia
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year - AOL.com
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 - BioSpace
Janux therapeutics doses first participant in JANX011 phase 1 trial - Investing.com Nigeria
Janux Therapeutics, Inc. (JANX) Investor Outlook: A Potential 383.93% Upside in the Biotech Sector - DirectorsTalk Interviews
Janux Therapeutics Announces First Patient Dosed In Phase 1 Study Of Janx011 - TradingView
Janux Therapeutics : JANX - 24/7 Wall St.
Published on: 2026-02-15 18:41:23 - mfd.ru
Trading the Move, Not the Narrative: (JANX) Edition - Stock Traders Daily
Is Janux Therapeutics Inc. forming a bullish divergenceQuarterly Risk Review & Risk Controlled Stock Pick Alerts - mfd.ru
What is Janux Therapeutics Inc.’s valuation compared to sectorMarket Performance Recap & Low Drawdown Momentum Trade Ideas - mfd.ru
Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring a Potential 379% Upside in Biotech Innovations - DirectorsTalk Interviews
Breakout Watch: What is Janux Therapeutics Incs debt to equity ratioDividend Hike & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Janux Therapeutics Inc (JANX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):